For millions living with debilitating symptoms after an infectious illness — from Lyme disease to COVID-19 — the absence of reliable biomarkers and reproducible research has meant years of diagnostic limbo and therapeutic dead ends. A rigorous methodological review published in Brain argues that the field has systematically undercut itself, and that fixing the science is prerequisite to finding treatments.
The review examines four overlapping infection-associated chronic illnesses (IACIs): post-treatment Lyme disease syndrome (PTLDS), long COVID, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), and multiple sclerosis. Across this spectrum, the authors identify a core problem: diagnostic ambiguity combined with heterogeneous patient presentations has enabled systematic misclassification of study participants, leading to inconsistent and irreproducible findings. The review calls for microbiologically confirmed infection status as an enrollment criterion where feasible, standardized biospecimen collection protocols, and carefully chosen control groups that can isolate the post-infectious state from confounders with overlapping symptom profiles. The authors also raise a less-discussed issue — that stigma, historical neglect of these conditions, and pressure to deliver treatments quickly have warped study design in ways that compound the reproducibility crisis.
This analysis lands at a consequential moment. Long COVID alone has added tens of millions of patients globally to a research pipeline that was already struggling to characterize PTLDS and ME/CFS. These conditions share not just symptoms but a common methodological vulnerability: no validated objective biomarker exists to confirm diagnosis, leaving enrollment criteria largely symptom-based and thus porous. The review's emphasis on microbiological proof-of-prior-infection as an anchor for cohort design is sound but logistically demanding — most patients arrive in research settings long after acute infection, limiting retrospective confirmation. As a framework paper rather than a primary data study, this work's impact will depend on whether funding bodies and trial designers actually adopt its recommendations. Its publication in a high-profile neurology journal may help translate methodology into policy. Incremental in scope, but potentially directionally important for a field in urgent need of scientific credibility.